Jefferies Financial Group Lowers IQVIA (NYSE:IQV) Price Target to $255.00

IQVIA (NYSE:IQV) had its target price decreased by research analysts at Jefferies Financial Group from $270.00 to $255.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Jefferies Financial Group’s price target indicates a potential upside of 36.00% from the company’s previous close.

IQV has been the topic of several other reports. Barclays decreased their target price on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Friday. BMO Capital Markets set a $250.00 target price on IQVIA in a report on Friday. Citigroup decreased their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday. Evercore reiterated an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a research note on Thursday. Finally, Morgan Stanley boosted their target price on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $241.75.

IQVIA Stock Up 3.6%

IQVIA stock opened at $187.50 on Friday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The firm has a fifty day moving average price of $228.03 and a two-hundred day moving average price of $209.77. The firm has a market cap of $31.93 billion, a price-to-earnings ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same period in the previous year, the business posted $3.12 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Alliancebernstein L.P. raised its holdings in IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after purchasing an additional 41,643 shares during the last quarter. Boston Partners acquired a new position in IQVIA during the 3rd quarter valued at about $676,698,000. Artisan Partners Limited Partnership lifted its position in IQVIA by 4.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

More IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.